Related Experiment Video

Updated: Apr 16, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.7K

Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma

Zhenyu Xiao1, Haniee Chung1, Babak Banan1

  • 1Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.

Cancer Letters
|February 28, 2015
PubMed

Insights

Targeting CD47 with antibodies shows promise for treating human hepatocellular carcinoma (HCC). This approach enhances immune cell activity against cancer cells, inhibiting tumor growth and metastasis in preclinical models.

Area of Science:

  • Immunology
  • Oncology
  • Hepatocellular Carcinoma Research

Background:

  • Hepatocellular carcinoma (HCC) presents significant challenges due to high recurrence and metastasis rates.
  • Current systemic therapies for HCC demonstrate limited efficacy, necessitating novel treatment strategies.

Purpose of the Study:

  • To investigate the potential of CD47-blocking antibodies as an immunotherapeutic approach for human HCC.
  • To evaluate the impact of CD47 blockade on HCC tumor growth and immune cell activity in preclinical models.

Main Methods:

  • Utilized xenograft tumor models to assess the efficacy of CD47 blockade.
  • Performed immunostaining to confirm CD47 overexpression in HCC tissues and cell lines.
  • Administered CD47-blocking antibodies (CD47mAbs) and analyzed effects on macrophage phagocytosis, tumor growth, and immune cell infiltration.

Main Results:

  • Confirmed significant CD47 overexpression in HCC compared to normal hepatocytes.
  • Demonstrated increased macrophage phagocytosis of HCC cells upon CD47 antibody treatment.
  • Observed inhibition of tumor growth in both heterotopic and orthotopic HCC models with CD47 blockade.
  • Noted enhanced migration of macrophages into the tumor microenvironment following CD47 targeting.

Conclusions:

  • Targeting CD47 with specific antibodies exhibits potential as an immunotherapeutic strategy for human HCC.
  • CD47 blockade can enhance anti-tumor immunity by promoting macrophage-mediated phagocytosis and infiltration.
  • This approach offers a promising avenue for improving outcomes in patients with hepatocellular carcinoma.
Keywords:
Antibody therapyCD47HCCXenograft models

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.2K
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

2.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K